摘要
目的探讨多种肿瘤生物标志物联合检测对胃癌的辅助诊断价值。方法选取经内镜和组织病理学确诊的胃癌患者200例,内镜确诊的胃良性疾病患者100例及正常对照组80例。对以上疾病组和对照组血清常用肿瘤标志物进行检测,CEA、CA19-9及CA72-4采用电化学发光法,CA24-2、PGI及PGII采用ELISA方法。结果胃癌组血清CEA、CA19-9、CA24-2及CA72-4较对照组明显升高,其差异具有统计学意义,良性对照与健康对照组间比较无统计学差异(P>0.05)。单独检测血清CEA、CA19-9、CA72-4及CA24-2,对胃癌诊断的敏感度最高的是CEA(42%),而多个指标联合检测对胃癌诊断敏感性为53.0%。胃癌患者治疗后血清CEA、CA19-9、CA24-2及CA72-4明显降低,与治疗前相比其差异具有统计学意义(P<0.01)。胃癌复发患者血清CEA、CA19-9和CA24-2明显升高。另外,伴粘膜萎缩炎症的胃癌组患者血清PGI和PGI/PGII比值明显降低,与对照组比较均具有非常显著差异(P<0.01)。结论低血清PGI及PGI/PGII有助于临床对胃粘膜状况的判断,多种肿瘤标志物联合检测可以改善胃癌诊断的阳性率,对复发的判断更具重要价值。
Objective To evaluate the clinical assistant diagnostic significance of multi-tumor markers in Gastric cancer（ GC ）. Methods 200 patients with definitive diagnostic GC were detected by upper gastrointestinal endoscopy and histopathological examination of endoscopic biopsy, 100 patients with benign digestive disease and 80 normal controls were diagnosed by endoscopy. The common serum tumor markers CEA, CA19-9 and CA72-4 of all patients and controls were detected by Electrochemiluminescence Immunoloassay （ ECLIA）, and CA24-2 ,PGI and PGII in serum were measured by Enzyme Linked Immunosorbent Assay （ELISA）. Results Serum levels of multiple tumor markers were significantly higher in the GC than those in the benign digestive disease and healthy control groups（ CEA, CA19-9 and CA24-2 ,P 〈 0.01 respectively ; CA72-4 ,P 〈 0.05 ）, and there was no significant difference between benign digestive disease groups and the healthy control（P 〉 0.05 ）. With a single tumor marker for GC diagnosis, the sensitivity of CEA was the highest （42%）. Combined detection of the tumor markers could increase the sensitivity of diagnoses in patients with GC （ 53% ）. The serum levels of CEA, CA19-9, CA24-2 and CA72-4 were significantly decreased in post-treatment patients with GC than in those with pretreatment patients（P 〈0.01 ）, and the levels of serum CEA, CA19-9 and CA24-2 of the recurrence patients with GC increased significantly. Moreover, as atrophy was observed in patients with GC, PGI and PGI/PGII-ratio levels were significantly decreased compared with the controls（ P 〈 0.01 ）. Conclusion The patients with low levels of serum PGI and PGI/PGII-ratio may be strongly associated with high risk forgastric cancer. Combined detection of serum muhi-biomarkers can improve the positive rate of diagnosis of gastric cancer, and have more significance in judging the recurrence.
出处
《标记免疫分析与临床》
CAS
2016年第1期1-4,共4页
Labeled Immunoassays and Clinical Medicine
